Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression

17th July 2025 Uncategorised 0

First patient dosed in BUOY-1 study targeting MDD with or without anxious distress

More: Seaport Therapeutics begins phase 2b trial of GlyphAllo for major depression
Source: News